title: Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).
abstract: Photosensitivity to sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is reported. No previous reports of photosensitivity to any DPP-4 inhibitors are known. Physical examination of the patient revealed edematous plaques confined to sun-exposed areas of the skin. An unusual finding in this case was the spongy sensation upon palpation of the plaques. Histopathology revealed parakeratosis and abundant eosinophils, supporting the clinical impression of cutaneous drug sensitivity. The eruption finally cleared, approximately two years after onset.
authors.affiliation: Stoecker & Associates, Rolla, Missouri, USA.
authors.forename: Sherea M
authors.initials: SM
authors.lastname: Stricklin
authors.forename: William V
authors.initials: WV
authors.lastname: Stoecker
authors.forename: Ryan K
authors.initials: RK
authors.lastname: Rader
authors.forename: Antoinette F
authors.initials: AF
authors.lastname: Hood
authors.forename: Jerome Z
authors.initials: JZ
authors.lastname: Litt
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Schuman
mesh_terms: D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D010787:Photosensitivity Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D011481:Protective Clothing; D011719:Pyrazines / Q000009:adverse effects*; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate